On July 22, Regeneron Pharmaceuticals declined 3.28% in regular trading, trading at $653.04/share, with turnover of $129 million. The stock came under pressure as multiple investment banks simultaneously lowered their price targets on the company.

On the news front, Cantor Fitzgerald cut its target price from $785 to $750 on July 22, while Goldman Sachs trimmed its target from $968 to $965, maintaining a buy rating. HSBC made a more aggressive move, slashing its target from $990 to $800. The consensus mean price target among analysts polled stands at approximately $825. The concentrated downgrades reflect growing caution toward the company's near-term outlook.

Adding to the headwinds, Regeneron disclosed in an SEC filing earlier this month that it expects Q2 GAAP and non-GAAP diluted EPS to decrease by approximately $1. The company is scheduled to report Q2 earnings on July 30 pre-market, with consensus EPS estimates at $8.00. Additionally, the overhang from the May fianlimab plus cemiplimab Phase 3 trial failure in advanced melanoma — where median PFS improvement of 5.1 months did not reach statistical significance (P=0.0627) — continues to weigh on investor sentiment regarding the company's oncology pipeline competitiveness.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)